Pages Menu
FacebookTwitterPinterestRss
Categories Menu

Posted by on Jan 28, 2015 in Foundation NewsLine |

Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Development Efforts Adult Trial ~ January 28th, 2015

Dear NNPDF Families and Friends,
The NNPDF is pleased to provide you with the following update from Genzyme, a Sanofi Company, on NEWLY released information about the adult Phase 2 / 3 clinical trial of recombinant human acid sphingomyelinase (rhASM).
Visit the NNPDF Genzyme web page to view the full announcement: https://www.nnpdf.org/npresearch_11.html#Jan282015
Please be advised of the following details associated with the adult Phase 2 / 3 clinical trial #: NCT02004691:
  • The study is NOT yet open for patient recruitment
  • Inclusion / Exclusion criteria are provided in the post
  • Estimated enrollment of 35 adult patients
  • MUST be 18 years and older
  • The number of country clinical sites and locations has NOT yet been determined ~ but there will be clinic sites in multiple countries.
(function($) { function setup_collapsible_submenus() { var $menu = $('#category_mobile_menu'), top_level_link = '#category_mobile_menu .page_item_has_children > a'; $menu.find('a').each(function() { $(this).off('click'); if ( $(this).is(top_level_link) ) { $(this).attr('href', '#'); } if ( ! $(this).siblings('.children').length ) { $(this).on('click', function(event) { }); } else { $(this).on('click', function(event) { event.preventDefault(); $(this).parent().toggleClass('visible'); }); } }); } $(window).load(function() { setTimeout(function() { setup_collapsible_submenus(); }, 700); }); })(jQuery);